, /PRNewswire/ -- IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to address IgE-mediated diseases, presented data on the company's lead candidate, IGNX001, an IgG4 monoclonal antibody-based therapeutic candidate for peanut allergy. The company also presented data in Atopic Dermatitis (AD), showcasing the widespread utility of its proprietary SEQ SIFTERTM antibody discovery platform in IgE-mediated disease beyond allergies.
These data were presented during the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting, which took place in on – . "At IgGenix, we're developing revolutionary treatments for peanut and other severe allergies. These therapeutics are designed to offer an appealing alternative for allergic patients that want protection against allergen exposure in a matter of days instead of months," said , Ph.
D., Chief Technical Officer of IgGenix. "Our pioneering SEQ SIFTER discovery platform is also unlocking IgE biology in an unprecedented way and we are excited to be working with our fantastic European collaborators on this new direction.
" IgGenix will be launching its first human clinical trial in peanut allergy later this year. IGNX001 Inhibits Peanut-Mediated Mast Cell Activation in a Translational Spike-In Assay Croote D., Bachmeier-Zbären N.
, Eggel A., Thomas GR., Lowman HB.
, Ph.D., IgGenix Discovery of Monoclonal IgE Autoantibodies from Atopic Dermatitis Patients Croote D.
, W.
